Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831383 · ClinicalTrials.gov registry record · NA
The STOP-HPV Scale Up Study
A NA study of Human Papilloma Virus Vaccine, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 100,000
- Enrollment target
- 1
- Study location
NCT06831383 is a NA study of Human Papilloma Virus Vaccine that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 100,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06831383, a NA study of Human Papilloma Virus Vaccine, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 100,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost effectiveness of two potentially scalable implementation strategies (based on prior work) to increase the initiation of HPV vaccine against a usual care (control) arm. The intervention arms are 1) online provider communication training only ("STOP-HPV-Online" and 2) online provider communication training plus a Learning Collaborative, with performance feedback, attended by practice leads ("STOP-HPV-LC). cer-related costs. It is recommended at ages 11-12 years routinely but can be given starting at ages 9-10 years. Despite having an effective vaccine, HPV vaccine initiation/completion rates in the U.S. were only at 76.8%/61.4% respectively in 2023 among 13-17 year olds; these rates are lower than the other recommended adolescent vaccines. Two key barriers are 1) suboptimal clinician communication to address parental concerns and 2) ineffective office systems causing missed vaccine opportunities.
Conditions Studied
Interventions
- BEHAVIORAL STOP-HPV-Online
- BEHAVIORAL STOP-HPV-LC
Study Locations (1)
Virginia
- AMGA - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100,000 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2027-04-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831383
The ClinicalTrials.gov registry entry for NCT06831383 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papilloma Virus Vaccine appearing as the primary indexed condition, and to 2 interventions - of which STOP-HPV-Online is the first listed.
NCT06831383 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06831383 about?
NCT06831383 is a clinical study titled "The STOP-HPV Scale Up Study". Human papillomavirus (HPV) causes 35,900 US cancer cases per year, 4,000 deaths, and $4 billion in can In this study, the investigators will conduct a 3-arm clustered randomized controlled trial (RCT) in an estimated 72 practices from up to 8 health systems to evaluate the effectiveness and cost eff...
What is the current status of trial NCT06831383?
This trial is currently recruiting. It is a NA study. The enrollment target is 100,000 participants. The study started on 2026-03-23. Estimated completion is 2027-04-19.
What conditions does trial NCT06831383 study?
This clinical trial studies the following conditions: Human Papilloma Virus Vaccine.
What interventions are being tested in trial NCT06831383?
The interventions under investigation include: STOP-HPV-Online (BEHAVIORAL), STOP-HPV-LC (BEHAVIORAL).
Who is sponsoring clinical trial NCT06831383?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831383 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papilloma Virus Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.